105 related articles for article (PubMed ID: 16442710)
1. Interleukin-6 level in patients with colorectal cancer.
Esfandi F; Mohammadzadeh Ghobadloo S; Basati G
Cancer Lett; 2006 Nov; 244(1):76-8. PubMed ID: 16442710
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma.
Chung YC; Chaen YL; Hsu CP
Anticancer Res; 2006; 26(5B):3905-11. PubMed ID: 17094421
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
[TBL] [Abstract][Full Text] [Related]
4. [The levels of selected cytokines in patients with colorectal cancer--a preliminary report].
Grotowski M; Piechota W
Pol Merkur Lekarski; 2001 Oct; 11(64):327-9. PubMed ID: 11770312
[TBL] [Abstract][Full Text] [Related]
5. Preoperative interleukin-6 production by mononuclear blood cells predicts survival after radical surgery for colorectal carcinoma.
Clinchy B; Fransson A; Druvefors B; Hellsten A; Håkansson A; Gustafsson B; Sjödahl R; Håkansson L
Cancer; 2007 May; 109(9):1742-9. PubMed ID: 17345614
[TBL] [Abstract][Full Text] [Related]
6. Expression of interleukin-17 in human colorectal cancer.
Wägsäter D; Löfgren S; Hugander A; Dimberg J
Anticancer Res; 2006; 26(6B):4213-6. PubMed ID: 17201135
[TBL] [Abstract][Full Text] [Related]
7. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
[TBL] [Abstract][Full Text] [Related]
8. Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer.
Albrethsen J; Møller CH; Olsen J; Raskov H; Gammeltoft S
Eur J Cancer; 2006 Nov; 42(17):3057-64. PubMed ID: 17015013
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer.
Miyazaki T; Okada N; Ishibashi K; Ogata K; Ohsawa T; Ishiguro T; Nakada H; Yokoyama M; Matsuki M; Kato H; Kuwano H; Ishida H
Jpn J Clin Oncol; 2008 Dec; 38(12):839-43. PubMed ID: 18923001
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.
Hsia CY; Huo TI; Chiang SY; Lu MF; Sun CL; Wu JC; Lee PC; Chi CW; Lui WY; Lee SD
Eur J Surg Oncol; 2007 Mar; 33(2):208-12. PubMed ID: 17140760
[TBL] [Abstract][Full Text] [Related]
11. [Receptors of selected cytokines and angiokine bFGF in patients with colorectal cancer (a preliminary study)].
Grotowski M; Piechota W
Pol Merkur Lekarski; 2001 Nov; 11(65):398-401. PubMed ID: 11852807
[TBL] [Abstract][Full Text] [Related]
12. Total and lipid-bound plasma sialic acid as diagnostic markers in colorectal cancer patients: correlation with cathepsin B expression in progression to Dukes stage.
Sebzda T; Saleh Y; Gburek J; Warwas M; Andrzejak R; Siewinski M; Rudnicki J
J Exp Ther Oncol; 2006; 5(3):223-9. PubMed ID: 16528972
[TBL] [Abstract][Full Text] [Related]
13. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
[TBL] [Abstract][Full Text] [Related]
14. [Tissue inhibitor of metalloproteinase-1 (TIMP-1) in colorectal cancer: correlation with clinico-morphological factors].
Korotkova EA; Gershteĭn ES; Prorokov VV; Kushlinskiĭ NE
Vopr Onkol; 2009; 55(2):171-6. PubMed ID: 19514370
[TBL] [Abstract][Full Text] [Related]
15. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
16. [A dynamic observation on serum cytokine and immunoglobulin (IgG, IgA, IgM) in patients with esophageal cancer].
Tang RG; Yuan XH; Tang TT; Tang XQ; Hang YQ; Qin HJ; Chen HM; Fang WZ; Long XK
Zhonghua Yu Fang Yi Xue Za Zhi; 2007 Jun; 41 Suppl():35-8. PubMed ID: 17767855
[TBL] [Abstract][Full Text] [Related]
17. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Harris AL;
J Clin Oncol; 2006 Sep; 24(26):4301-8. PubMed ID: 16896001
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor.
Abdel-Aziz MM; Lotfy M; El-Kady IM; Abozaid M
Cancer Detect Prev; 2009; 32(4):329-35. PubMed ID: 16632243
[TBL] [Abstract][Full Text] [Related]
19. [Serum level and genotype of interleukin-6 in patients with esophageal cancer].
Tang RG; Wei YS; Chen HM; Fang WZ; Long XK; Yuan XH
Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(16):1126-8. PubMed ID: 17672997
[TBL] [Abstract][Full Text] [Related]
20. Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival.
Yoo PS; Sullivan CA; Kiang S; Gao W; Uchio EM; Chung GG; Cha CH
Ann Surg Oncol; 2009 Jan; 16(1):200-7. PubMed ID: 19009247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
